American Journal of Neuroradiology 25:201-209, February 2004
© 2004 American Society of Neuroradiology
BRAIN
Diffusion-Weighted Imaging in the Follow-up of Treated High-Grade Gliomas: Tumor Recurrence versus Radiation Injury
a Section of Radiation Oncology, Norris Cotton Cancer Center, Lebanon, NH
b Department of Radiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Address reprint requests to Patrick A. Hein, MD, Department of Radiology, Charité, Humboldt Universitaet zu Berlin, Schumannstr. 20/21, 10098 Berlin, Germany
BACKGROUND AND PURPOSE: Diffusion-weighted (DW) MR imaging is a means to characterize and differentiate morphologic features, including edema, necrosis, and tumor tissue, by measuring differences in apparent diffusion coefficient (ADC). We hypothesized that DW imaging has the potential to differentiate recurrent or progressive tumor growth from treatment-induced damage to brain parenchyma in high-grade gliomas after radiation therapy.
METHODS: We retrospectively reviewed follow-up conventional and DW MR images obtained starting 1 month after completion of radiation treatment with or without chemotherapy for histologically proved high-grade gliomas. Eighteen patients with areas of abnormal enhancing tissue were identified. ADC maps were calculated from echo-planar DW images, and mean ADC values and ADC ratios (ADC of enhancing lesion to ADC of contralateral white matter) were compared with final diagnosis. Recurrence was established by histologic examination or by clinical course and a combination of imaging studies.
RESULTS: Recurrence and nonrecurrence could be differentiated by using mean ADC values and ADC ratios. ADC ratios in the recurrence group showed significantly lower values (mean ± SD, 1.43 ± 0.11) than those of the nonrecurrence group (1.82 ± 0.07, P < .001). Mean ADCs of the recurrent tumors (mean ± SD, 1.18 ± 0.13 x 10-3 mm/s2) were significantly lower than those of the nonrecurrence group (1.40 ± 0.17 x 10-3 mm/s2, P < .006).
CONCLUSION: Assessment of ADC ratios of enhancing regions in the follow-up of treated high-grade gliomas is useful in differentiating radiation effects from tumor recurrence or progression.